Shares of Frontier Communications Corp (NASDAQ:FTR), inclined 5.08% to $5.38, during its last trading session. In the last trading session, the stock moved on low volume, trading at a volume of 20.29 M as compared to its average daily volume of 21.85 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 13.26% which was maintained at 0.82% in 1-month period.
Frontier Communications Corp, plans to release third-quarter 2015 results on Tuesday, November 3, 2015 before the market opens, and to host a conference call that morning at 8:30 A.M. EST.
Frontier Communications Corporation, a communications company, provides regulated and unregulated voice, data, and video services to residential, business, and wholesale customers in the United States.
On Wednesday, Shares of AbbVie Inc (NYSE:ABBV), gained 0.98% to $55.62. The stock attained the volume of 11.08 million shares.
The year-to-date (YTD) performance reflected a -13.00% below last year. During the past month the stock loses -8.16%, bringing three-month performance to -17.55% and six-month performance to -6.32%. The stock holds the market capitalization of 92.08B.
Full results from the Phase 3 DECIDE study published this week in the New England Journal of Medicine (NEJM), in addition to new post-hoc analyses of Phase 3 clinical data presented at an international congress, show once-monthly, investigational ZINBRYTA™ (daclizumab high-yield process [HYP]) improved results on key measures of multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS (RRMS) contrast to interferon beta-1a 30 mcg intramuscular (IM) injection. In the new post-hoc analyses, ZINBRYTA was shown to improvement the percentage of patients achieving no evidence of clinical and MRI disease activity, improve cognitive processing speed and reduce 24-week confirmed disability progression across a broad range of subgroups at two years contrast to interferon beta-1a IM. Lead investigators on behalf of Biogen (BIIB) and AbbVie (ABBV) presented these new findings recently at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain (7-10 October).
“The new DECIDE data presented at ECTRIMS provide further insight into the potential of daclizumab HYP to reduce MS disease activity, counting the efficacy it has demonstrated in reducing MS relapse rates, disability progression and brain lesion development,” said Ludwig Kappos, M.D., chair, Department of Neurology and head, MS-Research Group, University Hospital, Basel, Switzerland, and lead investigator for DECIDE. “Over the two years of data we analyzed, nearly twice as many patients treated with daclizumab HYP had no evidence of MS disease activity contrast to those taking an approved MS treatment.”
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of Key Energy Services, Inc. (NYSE:KEG), declined -1.53% to $0.689, during its last trading session. In the last trading session, the stock moved on high volume, trading at a volume of 7.66 M as compared to its average daily volume of 2.74 million shares.
The stock, as of recent close, has shown weekly upbeat performance of 45.89% which was maintained at 7.14% in 1-month period.
Equity Analysts at the Brokerage Firm, Iberia Capital, downgrades their rating on the shares of Key Energy Services, Inc. (NYSE:KEG). Iberia Capital has a Sector Perform rating on the shares. Formerly, the analysts had a Outperform rating on the shares. The rating by the firm was issued on September 21, 2015.
Key Energy Services, Inc. operates as an onshore rig-based well servicing contractor in the United States and internationally. It offers rig-based services, counting the maintenance, workover, and recompletion of existing oil wells; completion of newly-drilled wells; and plugging and abandonment of wells at the end of their lives, in addition to specialty drilling services to oil and natural gas producers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
